Heron Therapeutics receives expanded indications from the FDA for Zynrelef

Heron Therapeutics Inc. announced Zynrelef has received expanded indications from the FDA for use in soft tissue and additional orthopedic surgical procedures, according to a press release.
Zynrelef, a postoperative pain management drug, is an extended-release dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and low-dose meloxicam, according to the release.
Zynrelef previously received FDA approval for lower extremity total joint arthroplasty procedures in adults. It is now FDA approved for foot and ankle procedures and several procedures in which direct

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart